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2.1  Introduction 
Increasingly, both  private  and public  health  care institutions  in  the 
United  States are looking toward  medical cost-effectiveness analysis as 
they consider complex resource allocation decisions concerning medical 
technologies. Though many of its key ideas originated in the United States, 
medical cost-effectiveness analysis has, until recently. been more widely 
accepted and used in a number of European countries, as well as in Can- 
ada, Australia, and New Zealand. These countries share with the United 
States a significant concern about the role of new technology in increasing 
health care costs, but also have national health systems that are well posi- 
tioned with strong incentives to engage in formal technology assessment. 
The recent increase in interest in medical cost-effectiveness analysis in the 
United States differs from the experience with cost-effectiveness analysis 
in other countries in that the private sector has played a much larger role 
in the United States. In particular, the demand for cost-effectiveness analy- 
ses in  the United States appears to have been significantly influenced by 
the desire of pharmaceutical companies to collect evidence concerning the 
cost-effectiveness of their products in order to encourage managed care 
organizations to include their products on formularies. This is evident in 
both the recent establishment of the Association for Pharmaceutical Out- 
comes Research with the heavy involvement of the pharmaceutical indus- 
try and the tremendous increase in interest in pharmacoeconomics in the 
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industry. This demand is also evident in the recent upsurge in interest in 
attempting to inform and even standardize methods for cost-effectiveness 
analysis in order to establish comparability among studies and minimize 
the chance for investigators with vested interests to use areas of method- 
ological ambiguity to obtain desired results. This is most prominently evi- 
denced by the report of the Panel on Cost-Effectiveness  in Health and Medi- 
cine (Gold et al. 1996), but it is also shown by the work of Sloan (1995), 
the Task Force on Principles for Economic Analysis of Health Care Tech- 
nology (1996), and others. 
While attempting to enhance the comparability and validity of medical 
cost-effectiveness analyses, these recent efforts have also heightened the 
expectations for cost-effectiveness analyses and the scrutiny with which its 
methods are examined. This is perhaps particularly true of the report of 
the Panel on Cost-Effectiveness in Health and Medicine, which explicitly 
advocates that cost-effectiveness analyses adopt a “societal” perspective 
and asserts that the methods of cost-effectiveness  analysis that adopt such 
a perspective have their roots in classical welfare economics. 
This paper summarizes some recent and ongoing work in which I and 
others have been engaged that attempts to address the connection between 
the methods used in the most common form of medical cost-effectiveness 
analysis-that  which utilizes quality-adjusted  life years (QALYs)-and 
principles of welfare economics. While this paper is not intended to be a 
systematic review of this important topic, it aims to address two key issues 
concerning  the  connection  between  welfare  economics  and  cost- 
effectiveness analysis: the measurement of benefits and the measurement 
of costs, especially future costs. In both of these cases, the application of 
basic principles of economic analysis provides unique insights into areas 
of ongoing controversy that are not apparent from other approaches. For 
example, by relying upon the economic principle of revealed preference, it 
is possible to learn about the validity of QALYs as a measure of patient 
preferences. Similarly, by  defining a lifetime utility maximization model 
and deriving conditions for constrained maximization, formal models of 
utility maximization provide a framework for resolving methodological is- 
sues about the inclusion of costs in medical cost-effectiveness analysis. 
Though formal economic analysis could also be used to address other 
methodological issues in medical cost-effectiveness analysis, such as tech- 
niques for sensitivity analysis (Meltzer 1998) and challenges in incorpor- 
ating  distributional  concerns  into  cost-effectiveness analyses  (Wagstaff 
1991), these will not be discussed in order to focus attention on the issues 
of the measurement of benefits and costs. 
The paper proceeds as follows. Section 2.2 reviews the historical origins 
and development of cost-effectiveness analysis based on QALYs. Section 
2.3 addresses the use of  revealed preference measures to assess to what Theoretical Foundations of Medical Cost-Effectiveness  Analysis  99 
extent QALYs reflect patient preferences. Section 2.4 addresses the inclu- 
sion of future costs. Section 2.5 concludes. 
2.2  Historical Origins and Development of 
Cost-Effectiveness  Analysis Using QALYs 
Though  medical  cost-effectiveness  analysis  using  QALYs appears to 
have  originated  with  the work  of  Fanshel and Bush  (1970), its growth 
seems to have begun with the work of Milton Weinstein and William Sta- 
son (1 976) on the cost-effectiveness of the treatment of hypertension. Pub- 
lished  both  as a  substantial  and detailed  book  (Weinstein  and Stason 
1976) and in abbreviated form as an article in the New England Journal 
q#  Medicine  (Stason and Weinstein  1977), their work  first brought  into 
prominence the idea that the benefits of medical intervention be quantified 
in terms of life years weighted by quality adjustment factors between zero 
and one, in which zero is equivalent to death, and one to perfect health. 
Unlike analyses of the costs of achieving some fixed objective (often called 
cost-minimization  analysis), this approach aimed to permit  comparison 
of the value of expending resources to achieve alternative health-related 
objectives. The QALY framework was thus designed to serve as a general 
one under which  the costs and benefits of interventions  aimed at vastly 
different diseases might be compared. In the context of an increasing ac- 
ceptance within medicine of the idea that health care should attempt not 
only to minimize mortality but also to minimize morbidity, the concept of 
quality adjustment was key  to the attraction  to the concept of  quality- 
adjusted life expectancy. 
Weinstein  and Stason in turn refer to earlier work by  Weinstein  and 
Zeckhauser  (1  972) as providing the link  between  cost-effectiveness  and 
welfare maximization. In essence, the argument is that the condition im- 
plied by utility maximization (that marginal utility be proportional to mar- 
ginal cost for all goods purchased) implies that the ratio of marginal cost 
to marginal utility should be a constant. Interventions for which the ratio 
of costs to benefits exceeds that constant should be avoided, whereas inter- 
ventions for which that ratio is smaller should be adopted. Coming out of 
utility maximization, decisions guided by  these cost-effectiveness or cost- 
utility ratios are intended to direct resources toward efficient allocations 
generated  by  utility  maximization  under  classical  conditions.  Findings 
such as these motivate the connection  of cost-effectiveness analyses per- 
formed from a societal perspective to the realization of efficient allocations 
based on criteria of welfare economics (Weinstein 1995; Gold et al. 1996). 
The methods of cost-effectiveness analysis and to what extent, if  any, 
they provide a valid approach to resource allocation have long been sub- 
ject to debate. Some of this debate relates to dissatisfaction with utilitarian 100  David Meltzer 
models as a basis for resource allocation (e.g., La Puma and Lawlor 1990). 
A much larger portion of this literature, however, accepts these utilitarian 
underpinnings and asks whether the methods of cost-effectiveness  analysis 
are up to the task of identifying utility-maximizing choices. While by  no 
means intending to dismiss the concerns of this former group, the method- 
ological critiques of cost-effectiveness described later in this chapter fall 
into the latter group. As such, they may be viewed by some people as trying 
to fix a fundamentally flawed approach. This may be a valid criticism, but 
the importance of  the issues addressed by  cost-effectiveness analysis, its 
influence, and the lack of strong competitors to replace it suggest the need 
to probe into these issues even in the presence of concerns about whether 
the approach could ever be fully adequate to its task. 
2.3  Measurement of Benefits 
The attractiveness of quality-adjusted life years stems from its claim to 
be able to act as a global measure of preference for health-related deci- 
sions, allowing comparison of interventions that may have effects on length 
of life or quality of life for any intervention, regardless of  the disease to 
which it is applied. This is essential if comparisons are to be made across 
interventions affecting disparate diseases, as is required for resource allo- 
cation decisions in practice. 
However, the key concern about QALYs is their validity as measures of 
patient preferences. It is not an obvious proposition that people will prefer 
whichever lifestyle option that, when weighted between zero and one, will 
result in the highest number of  quality-adjusted  life years. Issues of risk 
aversion and the distribution of QALYs in a population are clearly crucial 
issues in this regard. Beyond this, however, there are more basic questions 
about the validity of QALYs even in the context of certainty. Are people 
truly indifferent between living two years with a quality of life weight equal 
to 0.5 or one year with a quality of life weight equal to l?  When quality 
weights are derived from linear analog (“Please rate health state X be- 
tween zero and one where zero is death and one is perfect health”) or ratio 
scalings (“How much bettedworse is health state X than health state Y?”), 
there is no reason to suspect that this restriction should hold. When qual- 
ity weights are derived from either standard gamble or time trade-off meth- 
ods, there is at least some theoretical structure that suggests that people 
who prefer the options described in the questions used to elicit quality of life 
weights should prefer options that maximize quality-adjusted life expec- 
tancy. For example, in the time trade-off method, people are asked whether 
they would prefer a longer life in less-than-perfect health or a shorter life 
in perfect health. Quality weights derived by this method could be consis- 
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and time t and there is no discounting (i.e., U = Q X  t). In the standard 
gamble method, people are asked to choose  between continuation  of a 
less-than-perfect health state or a gamble in which they are returned to 
full health with probability p and die immediately with probability (1 -  p). 
If people maximize expected utility and there is no discounting, resource 
allocations based  on quality of life estimates derived from this method 
may be consistent with utility maximization. 
Under these conditions, the validity of QALYs as an outcome measure 
comes down to an empirical question concerning whether the assumptions 
required for the logical consistency of QALYs are an adequate reflection 
of people’s preferences. The problem in  determining this, however, has 
been the absence of a “gold standard” by which to measure people’s actual 
preferences. In the absence of such a “gold standard,” the most common 
approach in the psychometric literature has been to elicit quality of life 
weights using multiple methods such as linear analog, standard gamble, 
and time trade-off, and then determine to what extent these measures are 
correlated (e.g., Blumenschein and Johannesson 1998). Studies of this type 
have often (though not universally) found substantial correlation among 
these measures. Nevertheless, this may suggest more that these measures 
are quantifying the same or similar concepts than representing patients’ 
actual preferences. 
An alternative approach to assess the validity of QALYs, which I am 
using in some ongoing work, relies instead on the idea of revealed prefer- 
ence-that  one can learn about people’s preferences based on the choices 
they  are observed  to make. Though  the term  “revealed preference”  is 
drawn from economics, the concept of revealed preference is indeed a-if 
not the-central  tenet of the practice of medicine: that the best therapy 
for a patient is identified by  informing the patient about her options and 
allowing her to choose. This naturally suggests an alternative approach to 
determine whether QALYs reflect patient preferences-to  test whether the 
gain  in  QALYs from  a  medical  intervention  predicts  whether  patients 
choose that intervention. 
We have been examining this question in the context of patient prefer- 
ences for intensive therapy for type I diabetes mellitus (Meltzer, Polonsky, 
and Tobian  1998). From the Diabetes Control and Complications Trial 
(DCCT; DCCT Research Group 1993), it is now known that the frequent 
glucose checks and increased insulin dosing required under intensive ther- 
apy for diabetes can help prevent the early changes that may eventually 
result in  the major  complications of diabetes such as blindness, kidney 
failure, and neuropathy that can often result in amputation. On the other 
hand, the frequent glucose checks and insulin doses required for intensive 
therapy may be burdensome for many individuals and result in more fre- 
quent hypoglycemic symptoms. The decision to follow intensive therapy 
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quality and length of life in the future; thus, the choice between intensive 
and conventional therapy is a natural application of QALYs. Indeed, the 
DCCT investigators developed and published a cost-effectiveness analysis 
of intensive therapy based on the DCCT data. This suggests that intensive 
therapy is highly  cost-effective, with an average cost of  $19,987/QALY 
(DCCT Research Group 1996).  It is perhaps revealing about the ability of 
QALYs to reflect patient preferences that, despite this finding, many pa- 
tients who are aware of the DCCT results, and even many who bear no 
out-of-pocket expenses for their care, have not elected to pursue inten- 
sive therapy. 
In our work, my colleagues and I have surveyed approximately 130 pa- 
tients with diabetes on either intensive or conventional therapy who are 
similar to the population examined in the DCCT to ask them all the ques- 
tions necessary to calculate their quality-adjusted life expectancy with and 
without intensive therapy. The predicted gain in quality-adjusted life ex- 
pectancy from intensive therapy is then compared to their actual choice 
of  therapy to see if  those people with the greatest gain in  QALYs from 
intensive therapy are in fact those who choose intensive therapy. Because 
factors other than patient preferences, such as cost and the preferences of 
physicians, may also affect choice, we  have also collected information on 
these factors, although our initial analyses do not suggest any substantial 
role for these factors in the choice of therapy in our study population. 
While we have not yet completed our calculation of the gain in QALYs 
resulting from intensive or conventional treatment for each patient, prelim- 
inary analyses using logistic regression demonstrate that the elements used 
to calculate QALYs do predict choice. Specifically, we  find that patients 
are more likely to report themselves as having chosen intensive therapy 
when they report the beliefs that (1) quality of life would be relatively lower 
with complications of diabetes, (2) quality of  life is little affected by  the 
demands of intensive therapy, (3) intensive therapy will reduce the likeli- 
hood of complications, and (4) the future is more important than the pres- 
ent (a positive rate of  time preference). Combining these elements in  a 
logistic regression, it is possible to plot a receiver operating characteristic 
(ROC) curve (figure 2. l), which has what to many may seem a surprisingly 
high area under the curve (0.84). This seems to suggest that the gain in 
QALYs has a substantial ability to predict a patient’s reported choice of 
therapy. For example, an appropriately chosen cutoff for this regression 
would correctly classify about 80 percent of patients as preferring intensive 
or conventional therapy. This may surprise many in the economics com- 
munity who have tended to view QALYs as having little connection to the 
actual preferences of  patients, and who strongly preferred willingness-to- 
pay approaches. The ability of the predicted gain in QALYs based on the 
decision model (as opposed to the rather less restrictive logistic regression Theoretical Foundations of Medical Cost-Effectiveness Analysis  103 
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Fig. 2.1 
Nore: Area under ROC curve = 0.8442. 
ROC curve for logistic regression of QALY elements on reported therapy 
form) to predict choice may be somewhat less than this, but need not nec- 
essarily be. 
Putting aside these issues of functional form, an important argument 
favoring the critics of the QALY approach is the possibility that any corre- 
spondence between choices and a gain in QALYs may reflect attempts of 
respondents to minimize cognitive dissonance. Cognitive dissonance is the 
idea that individuals experience an aversive state whenever their beliefs 
are inconsistent with their actions and may respond to minimize this dis- 
cordance by changing either their actions or their beliefs (Festinger 1957). 
One piece of evidence supporting the potential  importance of cognitive 
dissonance in determining how people respond to the questions used to 
calculate quality-adjusted life expectancy is a paper by  Krumins,  Fihn, 
and Kent (1988) that reports a very strong correspondence between pa- 
tients’ predicted gains in quality-adjusted life expectancy from surgery for 
benign prostatic hypertrophy and the incidence of patients’ selecting sur- 
gery. The irreversible nature of prostate surgery is  probably particularly 
likely to generate responses designed to minimize cognitive dissonance. 
Intensive therapy may be somewhat less affected by cognitive dissonance 
than prostate surgery. The reversible nature of the decision to follow inten- 
sive therapy presumably places an upper bound on the degree of cognitive 
dissonance,  because  people  for whom  that dissonance was  sufficiently 
large would presumably alter their decision. Nevertheless, we  find in our 
study that about one-third of patients who report themselves as following 
intensive therapy are actually on conventional  therapy according to the 
strict definition of the DCCT, suggesting that patients may hold a belief 
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Fig. 2.2  ROC curve for logistic regression of QALY elements on actual therapy 
Note: Area under ROC curve = 0.7318. 
intensive therapy even when their therapy is not fully intensive. Interest- 
ingly, the area under the ROC curve for the regression of patients’ answers 
to the QALY questions on actual choice of intensive therapy according to 
the DCCT definition is only 0.73 (fig. 2.2). This corresponds, for instance, 
to correctly classifying only two-thirds of  patients as preferring intensive 
or conventional therapy. Thus the relationship between the psychometri- 
cally measured preferences used to calculate QALYs and stated therapeu- 
tic choices may be  partially inflated by  attempts to minimize cognitive 
dissonance. Validation of QALYs that would not be contaminated by cog- 
nitive dissonance would presumably require elicitation of preferences in a 
prospective setting before patients had even considered the choice they 
might face. 
Given the diminution of the predictive power of  QALYs for actual as 
opposed to reported therapeutic choice, it seems likely that a prospective 
analysis of the validity of QALYs that would presumably not be affected 
by  attempts to minimize cognitive dissonance would suggest that QALYs 
are far less able to predict choice than is desirable. However, this has not 
yet been demonstrated, and even if it were shown to be the case, the re- 
vealed preference approach suggests that QALY measures might in time 
be improved by  seeking methods to develop QALY measures that better 
predict  choices. Thus,  rigorous  application  of the principle  of revealed 
preference offers the opportunity both to assess the validity of QALYs and 
potentially  to improve their validity. Moreover, the principle of revealed 
preference could be used to compare the preference measures based on 
QALYs to the preference measure that most economists have favored: will- 
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correct, the willingness-to-pay measure should outperform QALYs in pre- 
dicting  choice.  Though  willingness to pay  has  been  shown  to predict 
choice in some cases (Brookshire, Coursey, and Schulze 1987), many re- 
sults of willingness-to-pay studies are clearly incompatible with observed 
choices (e.g., Fisher, Chestnut, and Violette 1989). A healthy competition 
between willingness-to-pay measures and QALY measures of health out- 
comes to predict behavior is likely to advance the quality of both measures. 
In the meantime, prudent investigators must be cautious in interpreting 
the results of any cost-effectiveness study that depends on the accurate 
measurement of the value of improvements in outcomes using any unitary 
scale of outcomes, whether QALYs or willingness to pay. 
2.4  Measurement of Future Costs 
Formal economic models of utility maximization also provide a valuable 
framework  for considering  the measurement  of  costs in  medical  cost- 
effectiveness analysis. Though it is not controversial, justification for the 
insistence of cost-effectiveness analysts on the measurement of marginal 
as opposed to average costs, for instance, comes directly out of the margi- 
nal conditions for utility maximization. Similar reasoning about marginal 
changes in expenditures can be applied to address the question of when 
marginal adjustments in other medical expenditures that take place when 
a medical  intervention  is undertaken  need  to be considered  in a cost- 
effectiveness analysis (Meltzer 1997). 
Unlike the question of whether to calculate average or marginal cost- 
effectiveness  ratios, the question of whether to include future costs for “un- 
related” illnesses and future nonmedical costs has been highly controver- 
sial. Nevertheless, it is equally amenable to analysis in a utility maximiza- 
tion model. Indeed, it is likely that one reason that the controversy about 
future costs has persisted so long is that the question has been subject to 
little formal analysis. For instance, while analysts have consistently argued 
the need to include future costs for related illnesses, analysts have come 
to dramatically divergent conclusions about whether future unrelated and 
future nonmedical costs should be included. For example, early work in 
cost-effectiveness analysis by Weinstein (1  980) supported the inclusion of 
future costs for unrelated illnesses, arguing that “the cost of treating dis- 
ease that would not otherwise have arisen must be considered” (p. 240). 
Though a few studies, such as the Office of Technology Assessment evalua- 
tion of  influenza vaccination (US. Congress  1981), did at least consider 
this approach, the vast majority of studies have not included future costs 
for unrelated illnesses. Typical in justifying this approach is the argument 
of Louise Russell (1986) in “Is Prevention Better Than Cure?” where she 
argues, “Added years of life involve added expenditures for food, clothes, 
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whether the program is a good investment” (p. 36). Interestingly, Weinstein 
(1986) concurs about the exclusion of future nonmedical costs, but does 
so on the grounds that “the explicitly constrained resource is health care 
cost, and other costs are the price we  all willingly pay to live” (p. 196). 
Thus there is a sense from the literature that it is reasonable to count cer- 
tain costs while excluding others, though researchers disagree on which 
costs should fall into the two categories. 
The persistence of the controversy concerning the measurement of fu- 
ture costs probably is related to the lack of formal analysis of the issue. 
However, two papers recently published in the Journal of  Health Econom- 
ics, one by Alan Garber and Charles Phelps (1997) and another by myself 
(Meltzer  1997), have applied formal economic analysis to this question. 
Unfortunately, the papers come to somewhat different conclusions. The 
Garber and Phelps paper concludes that under a rather restrictive set of 
assumptions, a set of rankings that excludes future costs will be the same 
as a set of rankings that includes future costs. My paper uses a more gen- 
eral model to show that, in the general case, a cost-effectiveness analysis 
should include all future costs, whether medical or nonmedical. Moreover, 
the set of restrictions under which the rankings would be preserved when 
future unrelated and nonmedical costs are excluded is shown to be far 
more restrictive than is recognized in the paper by Garber and Phelps. The 
restrictions turn out to make cost-effectiveness analyses that exclude fu- 
ture costs incompatible with important goals of cost-effectiveness  analysis, 
such as comparing interventions at different ages and comparing interven- 
tions that have different effects on length of life and quality of life. Thus, 
the clear theoretical implication from a model of lifetime utility maximiza- 
tion  is  that  cost-effectiveness analyses  should  include  all  future  costs, 
whether medical or nonmedical. A corollary to this is that resource alloca- 
tion decisions for medical spending cannot be made efficiently in isolation 
from the nonmedical cost implications of those decisions, as is implicit in 
the approach advocated by Weinstein (1986) that views health care spend- 
ing as coming from a “health care budget.” 
A second critical result that comes out of  the analysis in the Meltzer 
(1997) paper is that analyses that fail to include future costs will be biased 
in favor of interventions that extend life over interventions that improve 
the quality of life, especially among the elderly. These effects of future costs 
are most precisely described in the context of lifetime utility maximization 
models, such as those described in Meltzer (1997). However, the essence 
of the effects of including future costs in medical cost-effectiveness anal- 
ysis can be described by breaking total costs into the sum of current costs 
and future costs and then assuming that future net resource use is equal 
to a constant amount C per life year multiplied by the number of life years 
saved (ALE).  In that case, the cost-effectiveness  ratio (cost per QALY) can 
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the cost-effectiveness ratio that 
only includes current costs. The second term in the equation describes the 
future costs that have traditionally  been  omitted from cost-effectiveness 
analyses. The equation implies that these costs will be largest when future 
costs per year of life lived (C) are large and when the ratio of the change 
in life expectancy to the change in quality-adjusted life expectancy is large. 
Meltzer (1997) develops some rough but useful estimates of C based on 
population  average data for consumption plus medical expenditures plus 
earnings by  age the United  States, suggesting that C varies from about 
-$10,000  at age  twenty  to about  +$20,000  at  age  seventy  and above. 
These  numbers  go  gradually  from  negative  to positive  because  young 
people on average produce more than they consume over their lifetime, 
whereas people who are older and have already passed through their work- 
ing years on average consume more than they produce after that age. Table 
2.1, reproduced from Meltzer (1997), uses these estimates and the approxi- 
mation described above, based on the ratio of effects on length of life and 
quality of life, to estimate the effects of including future costs on the cost- 
effectiveness of a number of common medical interventions. The interven- 
tions are listed in the table in order of diminishing cost-effectiveness based 
on traditional estimates that exclude future costs for unrelated  and non- 
medical expenditures. The last column then reports the cost-effectiveness 
ratio that includes these future costs. The results clearly show that the rel- 
ative rankings of interventions can change-rising  or falling based on the 
effects on length of life and quality of life and on the age of the patient at 
the time of the intervention, which can imply positive or negative annual 
costs. Many of the changes in rankings appear at the top of the table and 
may be considered substantively important by some analysts, though per- 
haps not by others because even the ratios that include future costs suggest 
that  the interventions  remain  relatively cost-effective by most  standards 
(i.e., <$50,000 -  $lOO,OOO/QALY Goldman et al. 1991). 
In contrast, some of the interventions at the bottom of the table imply 
larger changes that could alter whether an intervention is considered cost- 
effective. For example, the estimates that exclude future costs suggest that 
among sixty-year-old  men, the treatment  of  hypertension  and adjuvant 
chemotherapy for Duke's C colon cancer are both cost-effective compared 
to dialysis for end-stage renal disease that lies somewhat above the range Table 2.1  Effect of Future “Unrelated” Costs on the Cost per Quality-Adjusted Life Year 
Intervention 
Change in 
Bias Due  Change in Life  Quality-Adjusted  Annual 
Expectancy  Life Expectancy  Change in  Future Cost  to Future  Reported  Actual 
(LEI  (QAW  LEIQALE  (C)  cost  CostlQALY  CostIQALY 
Adjuvant chemotherapy for 
Duke’s C colon cancer 
age 55 (Smith et al. 1993) 
hypertension men age 40 
(Stason and Weinstein 
1977) 
Adjuvant chemotherapy for 
node-negative breast 
cancer age 45 (Hillner 
and Smith 1991) 
Adjuvant chemotherapy for 
node-negative breast 
cancer age 60 (Hillner 
and Smith 1991) 
Treatment of severe 
hypertension, men age 
50” (Stason and 
Weinstein 1977) 
Coronary artery bypass 
3-vessel disease, mild 
angina age 55 (Wong 
et al. 1990) 
Coronary artery bypass 
3-vessel disease, severe 
angina age 55 (Wong 
et al. 1990) 
Treatment of severe 
2.4 yr  0.4 yr  6.00  3,000  18,000 
4 Y‘  3.9 yr  1.03  -  5,000  -5,200 
11 mo  5.1 mo  2.16  -4,000  -8,700 
7.7 mo  4.0 mo  1.93  8,000  15,400 
2.6 yr  2.5 yr  1.04  0  0 
0.6 yr  0.7 yr  0.86  3,000  2,600 














48,300 Adjuvant chemotherapy for  2.9 mo 
node-negative breast 
cancer age 75 (Desch 
et al. 1993) 
therapy ages 55-65 
(Tosteson and Weinstein 
1991) 
Treatment of severe 
hypertension, men age 
60.' (Stason and 
Weinstein 1977) 
Adjuvant chemotherapy for 
Duke's C colon cancer 
age 60 (estimated based 
on Smith et al. 1993)b 
Hormone replacement  0.0458 YI- 
Hemodialysis for end-stage 
renal disease (ESRD) 
men aged 30 (estimated 
based on Garner and 
Dardis 1987 and 
Hornberger, Redelmeier, 
and Peterson 1992)' 
Hemodialysis for ESRD 
men aged 60 (estimated 
based on Garner and 
Dardis 1987 and 
Hornberger, Redelmeier, 





















32,200  54,000 
0,400  54,200 
86,200 
63,600 
8,500  60,000  68,500 
144,000  67,000  2 1 1,000 
0  1 17,000  1 17,000 
12,000  1 17,000  129,000 
Note; Costs converted to 1993 dollars using the medical CPI (US. Department of Labor 1994). 
"tason  and Weinstein already include future unrelated medical costs, so the additional future costs here refer only to consumption net of earnings. 
DEstimates  made for sixty-year-old  assuming life expectancy of sixteen years at age sixty as opposed to twenty years at age fifty-five used to calculate the 
cost-effectiveness at age fifty-five. 
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that people often cite as cost-effective. In contrast, when future costs are 
included,  the  cost-effectiveness of  adjuvant  chemotherapy  deteriorates 
markedly, rising to over $200,00O/QALY This large change in the cost- 
effectiveness  ratio occurs because chemotherapy has large effects on length 
of life compared to quality of life. This illustrates the quantitative signifi- 
cance of the potential for excluding future costs to bias analyses to favor 
interventions that extend life over those that improve the quality of life. 
Although  these estimates  of  the effects of including future costs are 
based on the approximations described above, which may be inaccurate 
for a variety of reasons, other work that I have done with Magnus Johan- 
nesson and Richard O’Conor on the cost-effectiveness of treatment for 
hypertension suggests that the estimates based on this approximation cor- 
respond fairly well to estimates that directly incorporate future costs into 
the cost-effectiveness analysis (Johannesson, Meltzer, and O’Conor 1997). 
Other work I am involved in that directly incorporates future costs into a 
cost-effectiveness analysis of hip replacement among the elderly--which 
provides its benefit by  improving quality  of  life-reinforces  the finding 
that excluding future costs favors interventions that extend life over those 
that improve the quality of life (Meltzer et al. 1998). A contrasting example 
to the case of hip replacement is that of prostate cancer treatment, which 
may not offer any advantage in life expectancy-no  less quality-adjusted 
life expectancy-because  of the potentially substantial negative effects of 
treatment on quality of life. However, even if treatment does offer an ad- 
vantage in life expectancy and quality-adjusted life expectancy, it is likely 
to have a small effect on quality-adjusted life expectancy compared to life 
expectancy. Indeed, the most optimistic cases considered by Fleming et al. 
(1  993) concerning the value of radical prostatectomy for moderately differ- 
entiated prostate cancer in sixty-five-year-old  men suggest an average gain 
in QALYs of 0.2 QALY compared to average gain in life expectancy of 0.7 
life year. This suggests a ratio of ALEIAQALY of 3.5, which, with a future 
cost C of $16,000 per year at age sixty-five, implies a cost-effectiveness 
ratio of $56,000 per year even if treatment of prostate cancer had no direct 
costs. Thus prostate cancer may be an excellent example of an intervention 
where the potential for negative effects on quality of life has important 
implications for cost-effectiveness. 
2.5  Conclusion 
This  review  has  focused  on  two  methodological  areas  in  cost- 
effectiveness analysis-the  validity of the measurement of benefits as qual- 
ity-adjusted life years and the appropriate treatment of future costs-in 
which reliance on economic theory can provide valuable methodological 
insights. On the benefits side, the concept of revealed preference provides 
evidence  consistent  with  the  hypothesis  that  patients  value  gains  in Theoretical Foundations of Medical Cost-Effectiveness Analysis  111 
QALYs, though the results may also be consistent with cognitive disso- 
nance. Ultimately, the results suggest the need for further work using re- 
vealed  preference  to  evaluate  and  improve  quality  of  life  measures, 
whether based on QALYs or willingness-to-pay measures, and suggest the 
need for caution in the interim whenever a study relies on such measures. 
On the cost side, models of lifetime utility maximization point out the need 
to include all future medical and nonmedical costs and also point out the 
bias in favor of interventions that extend life over the improvement in qual- 
ity of life that often occurs when such future costs are excluded. 
An important interaction between these two results relates to the depen- 
dence of the future-cost term on the ratio of changes in life expectancy to 
changes in quality-adjusted life expectancy. The presence of the change in 
QALYs in the denominator of this ratio implies a high degree of sensitivity 
of cost-effectiveness estimates to quality of life assessment. Thus the prob- 
lems in accurately measuring quality of life can have immense effects on 
cost-effectiveness, especially once future costs are considered. 
Though the application of insights from economic theory to the mea- 
surement of  benefits and costs in medical  cost-effectiveness analysis is 
important, there are other controversial issues in which economic theory 
may provide valuable insights into the methods needed to improve cost- 
effectiveness analysis as well. These include methods for sensitivity anal- 
ysis based on utility maximization (Meltzer  1998) and techniques to ad- 
dress distributional concerns (Wagstaff 1991). Though neither question is 
provided an unambiguous response by the application of utility maximiza- 
tion, the discussion generated by such models provides a key framework 
for understanding  these problems.  If  the influence of cost-effectiveness 
analysis is to continue to increase as it appears to be doing currently, and 
if it is to do more good than harm, it is crucial that its methods continue 
to undergo rigorous scrutiny. 
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Comment  Douglas L. Cocks 
This paper provides an extremely useful contribution to the field of health 
economics as it is applied to the economic evaluation of  pharmaceutical 
medical interventions. In recent years the quasi-application of economics 
to the evaluation of pharmaceuticals has come under the scrutiny of many 
diverse disciplines (medicine, pharmacy administration, sociology, psy- 
chology, business  administration, anthropology, statistics, and  others), 
which in turn derived the new discipline known as pharmacoeconomics. 
Dr. Meltzer’s discussion of  the  relationship between  the concept of 
Douglas L. Cocks is retired senior research scientist of health economics at Eli Lilly and 
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quality-adjusted life years (QALYs) and the economic concept of revealed 
preference  highlights the  possible notion  that  the  relationship between 
pharmacoeconomics and real health economic analysis is tenuous. The 
implication of the discussion is that the concept of  QALYs confuses the 
basic microeconomic distinction between cardinal and ordinal utility. In 
essence, the QALY designation is founded as a cardinal representation of 
utility and therefore cannot be translated into the true concepts of classical 
welfare economics. As the paper points out, even the report of  the Panel 
on Cost-Effectiveness in Health and Medicine “explicitly advocates that 
cost-effectiveness analyses adopt a ‘social’ perspective, and asserts that the 
methods of cost-effectiveness analysis that adopt such a perspective have 
their roots in classical welfare economics.” This cardinal orientation ren- 
ders the use of QALYs very limited, especially in making economic com- 
parisons of  drugs that are similar in therapeutic  activity and chemical 
makeup. 
The empirical data presented on the limitations of QALYs indicate that 
these measures are not necessarily a reliable measure of the economic sig- 
nificance of  a particular  medical intervention. The application of  tradi- 
tional microeconomic welfare economics to questions of the economic sig- 
nificance of medical interventions may be  the best guide to both public 
and private policy issues concerning these interventions. 
The second major part of the paper deals with the importance of dealing 
with future costs when analyzing the economic cost and benefits of medi- 
cal interventions. This is an extremely important concept that is often mis- 
understood  or forgotten in the field  of  pharmacoeconomics. This basic 
concept is related to an economic principle that is also misunderstood, the 
principle of the distinction between systems costs and component (some- 
times known as line item) costs.’ This distinction is  important because 
much of the management of health care in the United States and in certain 
foreign health care systems relies on the use of component management, 
rather than addressing health care costs from a systems perspective. The 
major economic issue is centered around resource allocation decisions. Re- 
source allocation decisions are grounded in production functions in clas- 
sical economics, which require an answer to the question What allocation 
of inputs results in the greatest output at the lowest cost? The case for a sys- 
tems approach, as opposed to a componentAine item approach, has been 
analyzed empirically. Several studies have shown that focusing on one 
component of cost without considering interaction effects can cause the 
unintended effect of increasing total costs even as the cost of the single com- 
ponent is reduced.2 
The concept of  systems management can be framed analytically in a 
I. This discussion is based on Cocks and Croghan (1996). 
2. Soumerai et al. (1994); Sloan, Gordon, and Cocks (1993); Moore and Newman (1993); 
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methodology of economics known as economic growth accounting. This 
methodology, developed by  Denison  (1974), was first applied to health 
care by Klarman et al. (1970) followed by Virts (1977) and Virts and Wil- 
son (1983, 1984). 
The fundamental notion of economic growth accounting is that health 
care costs cannot be addressed until they have been  broken down into 
their basic factors. From an economic perspective, these factors can be 
expressed in a simple identity, 
THE, = e.U,.N,, 
where THE, equals total health care expenditures in a given time period, 
t;  P,  is the price per unit of health care goods and services in time period 
t; U, is the utilization of health care goods and services-the  number of 
units of health care goods and services consumed perperson in time period 
t;  and N,  is the number of persons consuming health care goods and ser- 
vices in time period t.  Historically, identities have been used in economic 
analysis  to  convey  fundamental  economic  concepts  algebraically  and 
graphically. The most recognized identity is the equation for the quantity 
theory of money (Glahe 1973). 
The simple model  of  health care expenditures can be applied  to the 
many institutional forms that make up the total health care system. At the 
aggregate level, total U.S. health care expenditures represent the summa- 
tion  of  the many THE, equations emanating from the myriad of health 
care delivery systems. Thus, the analytic or managerial problem is to deter- 
mine how the level of total health care expenditures (THE,) changes over 
time and the relative contribution of each major element (P,, U,, and N,) 
to the growth in health care costs/expenditures. 
In applying the basic model, a fundamental issue highlights the impor- 
tance of a systems approach to health care management. Many interaction 
effects exist among the individual factors as those factors change both in 
magnitude and over time. For example, as the price of a good or service 
rises, the number of units purchased of that good or service usually falls. 
The price rise also results in increased consumption of an alternative or 
substitute good. These interaction effects are difficult to understand and 
even more difficult to account for numerically. 
The relationship among the factors can be observed by examining the 
simple mathematics of change derived from the expenditure/cost equation, 
THE, = P, . U,  . N,.  Therefore, the changes in spending can be expressed as 
ATHE = AP + AU  +AN  + (AP.AU)  + (AP.AN)  + (AN.AU) 
In this relationship, the terms are defined as follows: 
0  ATHE = THE, -  THE,-the  change in total health care expendi- 
tures is the difference in total health care expenditures in the given 
year, t,  and a beginning or base year, 0. 116  David Meltzer 
AP = P, -  Po-the  change in health care prices is the difference in 
the price level in the given year, t, and the base year, 0. 
AU = U, - U,-the  change in utilization is the difference in utiliza- 
tion in the given year, t, and the base year, 0. 
AN = N, - No-the  change in the number  of  persons consuming 
health care goods and services is the difference in the number of per- 
sons in the given year, t,  and the base year, 0. 
(AP . AU), (AP . AN), (AN. AU)-represents  the interaction effects 
that result from the individual factor changes that operate on each 
other. 
This simple model as it is presented represents the aggregation of health 
care expenditures at a total level. Thus, the total health expenditures term, 
THE,, represents the summation of expenditures for all the goods and 
services that  constitute  health  care  spending. In  simple mathematical 
terms, this can be expressed accordingly: 
THE, = CSPE,,, 
where CSPE,, is the summation of spending on specific health care goods 
and services, i, for the time period, t. The term CSPE,, represents the crux 
of the problem of managing health care costs. The management problem 
this model exposes has four dimensions: (1) the complexity inherent in 
examining the number of items that make up health care spending, CSPEI,; 
(2) the need to determine the contribution of each component of individual 
spending (PI, U,, and N,) to total expenditures, THE,; (3) the need to spe- 
cifically address the interaction effects among prices, utilization, and popu- 
lation (AP .  AU), (AP . AN), and (AN. AU); and (4) the need to examine 
substitutions among health care goods and services that take place with 
the summation of expenditures, XSPE,,. In economic terms, the last dimen- 
sion represents the need to address the elasticity of substitution among the 
various inputs that constitute total health care spending. 
The purpose of the preceding discussion is to emphasize the importance 
of Dr. Meltzer’s point on the significance of addressing the issue of future 
costs in cost-effectiveness studies. The economic implications of the intro- 
duction and use of innovative medical interventions  have many dimen- 
sions that must be addressed when considering the allocation of health re- 
sources. 
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